Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article contentVANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026.Sign In or Create an AccountEmail AddressContinueor View more offersArticle contentArticle contentConference Call/Webcast Information: Date:Monday, March 9, 2026 Time:8:00 am ET (5:00 am PT) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:7885306 Article contentWe apologize, but this video has failed to load.Try refreshing your browser, ortap here to see other videos from our team.Article contentTop StoriesGet the latest headlines, breaking news and columns.There was an error, please provide a valid email address.Sign UpBy signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInterested in more newsletters? Browse here.Article contentA live webcast of the company presentation will be available on the Investors section of Xenon’s website and posted for replay following the event. The above listed dates and times are subject to change.Article contentAbout Xenon Pharmaceuticals Inc.Article contentXenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.Article contentXenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.Article contentContactsArticle contentFor Investors:Tucker KellyChief Financial Officerinvestors@xenon-pharma.comArticle contentFor Media:Colleen AlabisoSenior Vice President, Corporate Affairsmedia@xenon-pharma.comArticle contentArticle contentArticle contentArticle contentArticle contentArticle contentTrending U.S. aluminum buyers hunt for alternatives as Iran war upends global supply Commodities Bank of Canada governor warns of growing risks to financial stability Economy South Bow confirms open season for new pipeline to the U.S. using legacy Keystone XL permits Oil & Gas This TSX stock fought its way back from the AI software rout and may have 'strong growth prospects' Investor Beer, wine sales fall even more, putting tax revenues on the rocks, but one boozy drink is on the rise Retail & Marketing Share this article in your social networkCommentsYou must be logged in to join the discussion or read more comments.Create an AccountSign in Join the Conversation Postmedia is committed to maintaining a lively but civil forum for discussion. Please keep comments relevant and respectful. Comments may take up to an hour to appear on the site. You will receive an email if there is a reply to your comment, an update to a thread you follow or if a user you follow comments. Visit our Community Guidelines for more information. U.S. aluminum buyers hunt for alternatives as Iran war upends global supply Commodities Bank of Canada governor warns of growing risks to financial stability Economy South Bow confirms open season for new pipeline to the U.S. using legacy Keystone XL permits Oil & Gas This TSX stock fought its way back from the AI software rout and may have 'strong growth prospects' Investor Beer, wine sales fall even more, putting tax revenues on the rocks, but one boozy drink is on the rise Retail & Marketing